Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05417386 · ClinicalTrials.gov registry record · Phase 1
FOLFIRINOX + NIS793 in Pancreatic Cancer
A Phase 1 study, sponsored by Colin D. Weekes, M.D., PhD.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT05417386 is a Phase 1 study that was terminated before completion, run by Colin D. Weekes, M.D., PhD. The registered enrollment target is 4 participants.
The verdict
NCT05417386, a Phase 1 study, was terminated before completion, sponsored by Colin D. Weekes, M.D., PhD.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This research is being done to evaluate the safety and effectiveness of the drug NIS793 in combination with the standard of care treatment FOLFIRINOX (consists of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin), chemoradiation and surgery for people with metastatic pancreas adenocarcinoma. The drugs involved in this study are: * NIS793 * FOLFIRINOX (consists of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin) Other interventions include * chemoradiation * surgery.
Interventions
- DRUG Leucovorin
- DRUG 5-Fluorouracil (5-FU)
- DRUG Oxaliplatin
- DRUG Irinotecan
- DRUG FOLFIRINOX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-08-09 |
| Est. Completion | 2023-07-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05417386
The ClinicalTrials.gov registry entry for NCT05417386 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Colin D. Weekes, M.D., PhD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Leucovorin is the first listed.
NCT05417386 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05417386 about?
NCT05417386 is a clinical study titled "FOLFIRINOX + NIS793 in Pancreatic Cancer". This research is being done to evaluate the safety and effectiveness of the drug NIS793 in combination with the standard of care treatment FOLFIRINOX (consists of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin), chemoradiation and surgery for people with metastatic pancreas...
What is the current status of trial NCT05417386?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2022-08-09. Estimated completion is 2023-07-10.
What interventions are being tested in trial NCT05417386?
The interventions under investigation include: Leucovorin (DRUG), 5-Fluorouracil (5-FU) (DRUG), Oxaliplatin (DRUG), Irinotecan (DRUG), FOLFIRINOX (DRUG).
Who is sponsoring clinical trial NCT05417386?
This trial is sponsored by Colin D. Weekes, M.D., PhD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.